Real-World Use of Once-Weekly Semaglutide in Thai Patients With Type 2 Diabetes Mellitus in a Private Hospital Setting.

IF 0.6 Q4 ENDOCRINOLOGY & METABOLISM

Journal of the ASEAN Federation of Endocrine Societies Pub Date : 2023-01-01 DOI:10.15605/jafes.038.01.11

Yotsapon Thewjitcharoen, Nalin Yenseung, Siriwan Butadej, Soontaree Nakasatien, Phawinpon Chotwanvirat, Waralee Chatchomchuan, Ekgaluck Wanothayaroj, Sirinate Krittiyawong, Thep Himathongkam

{"title":"Real-World Use of Once-Weekly Semaglutide in Thai Patients With Type 2 Diabetes Mellitus in a Private Hospital Setting.","authors":"Yotsapon Thewjitcharoen, Nalin Yenseung, Siriwan Butadej, Soontaree Nakasatien, Phawinpon Chotwanvirat, Waralee Chatchomchuan, Ekgaluck Wanothayaroj, Sirinate Krittiyawong, Thep Himathongkam","doi":"10.15605/jafes.038.01.11","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate the real-world use of once-weekly semaglutide among Thai patients with type 2 diabetes (T2DM) in a private hospital setting.Methodology: A retrospective review of Thai patients with T2DM who have initiated semaglutide for at least 1 month between June 2020 and March 2022 at Theptarin Hospital, Bangkok, Thailand.Results: A total of 58 patients (50% female, mean age 55.6 ± 15.9 years, with duration of diabetes 12.6 ± 10.3 years, BMI 31.5 ± 4.4 kg/m2, baseline HbA1c 7.9 ± 1.9%, with prior GLP-1 RA use 24.1%, and concomitant SGLT2i intake (41.4%) were included. During a median follow-up of 6 months, the mean serum HbA1c level reduction was 1.3 ± 1.7% with weight loss of 4.7 ± 4.1 kg. The proportion of patients who achieved optimal and sustainable glycemic control (HbA1c < 7.0%) increased from 43.1% to 55.8% at the last follow-up. The proportion of patients reaching both HbA1c targets of <7.0% and 5% weight loss was 27.8%. No cases of pancreatitis, cancer, or progressive retinopathy were observed.Conclusions: In this single center undertaking, it was shown that in among persons with T2DM and obesity in Thailand, semaglutide was associated with short-term glycemic control and weight loss comparable with what has been observed in randomized clinical trials and other RWE.","PeriodicalId":41792,"journal":{"name":"Journal of the ASEAN Federation of Endocrine Societies","volume":"38 1","pages":"21-28"},"PeriodicalIF":0.6000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ce/03/JAFES-38-1-21.PMC10213164.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the ASEAN Federation of Endocrine Societies","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15605/jafes.038.01.11","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To evaluate the real-world use of once-weekly semaglutide among Thai patients with type 2 diabetes (T2DM) in a private hospital setting.

Methodology: A retrospective review of Thai patients with T2DM who have initiated semaglutide for at least 1 month between June 2020 and March 2022 at Theptarin Hospital, Bangkok, Thailand.

Results: A total of 58 patients (50% female, mean age 55.6 ± 15.9 years, with duration of diabetes 12.6 ± 10.3 years, BMI 31.5 ± 4.4 kg/m², baseline HbA_1c 7.9 ± 1.9%, with prior GLP-1 RA use 24.1%, and concomitant SGLT2i intake (41.4%) were included. During a median follow-up of 6 months, the mean serum HbA_1c level reduction was 1.3 ± 1.7% with weight loss of 4.7 ± 4.1 kg. The proportion of patients who achieved optimal and sustainable glycemic control (HbA_1c < 7.0%) increased from 43.1% to 55.8% at the last follow-up. The proportion of patients reaching both HbA_1c targets of <7.0% and 5% weight loss was 27.8%. No cases of pancreatitis, cancer, or progressive retinopathy were observed.

Conclusions: In this single center undertaking, it was shown that in among persons with T2DM and obesity in Thailand, semaglutide was associated with short-term glycemic control and weight loss comparable with what has been observed in randomized clinical trials and other RWE.

Abstract Image

查看原文本刊更多论文

泰国私立医院2型糖尿病患者使用每周一次的西马鲁肽

目的:评估泰国私立医院2型糖尿病(T2DM)患者每周一次的西马鲁肽的实际使用情况。方法:对2020年6月至2022年3月期间在泰国曼谷Theptarin医院接受西马鲁肽治疗至少1个月的泰国2型糖尿病患者进行回顾性研究。结果:共纳入58例患者(50%为女性，平均年龄55.6±15.9岁，糖尿病病程12.6±10.3年，BMI 31.5±4.4 kg/m2，基线HbA1c 7.9±1.9%，既往GLP-1 RA使用24.1%，合并SGLT2i摄入41.4%)。在中位随访6个月期间，平均血清HbA1c水平降低1.3±1.7%，体重减轻4.7±4.1 kg。最后一次随访时，达到最佳持续血糖控制(HbA1c < 7.0%)的患者比例从43.1%上升到55.8%。结论:在这项单中心研究中，研究表明，在泰国T2DM和肥胖患者中，西马鲁肽与短期血糖控制和体重减轻有关，这与在随机临床试验和其他RWE中观察到的结果相当。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of the ASEAN Federation of Endocrine Societies ENDOCRINOLOGY & METABOLISM-

CiteScore

1.20

自引率

0.00%

发文量

审稿时长

8 weeks

期刊介绍： The Journal of the ASEAN Federation of Endocrine Societies (JAFES) is an OPEN ACCESS, internationally peer-reviewed, English language, medical and health science journal that is published in print two times a year by the ASEAN Federation of Endocrine Societies. It shall serve as the endocrine window between the ASEAN region and the world, featuring original papers and publishing key findings from specialists and experts of endocrinology.